Rivastigmine + Placebo
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Delirium
Conditions
Delirium
Trial Timeline
Nov 1, 2008 → May 1, 2010
NCT ID
NCT00704301About Rivastigmine + Placebo
Rivastigmine + Placebo is a approved stage product being developed by Novartis for Delirium. The current trial status is terminated. This product is registered under clinical trial identifier NCT00704301. Target conditions include Delirium.
What happened to similar drugs?
4 of 12 similar drugs in Delirium were approved
Approved (4) Terminated (2) Active (6)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00704301 | Approved | Terminated |
Competing Products
17 competing products in Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 42 |
| Suvorexant + Placebo | Merck | Phase 3 | 40 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 35 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 40 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 40 |
| Rivastigmine Patch | Novartis | Approved | 43 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 32 |
| Parecoxib | Pfizer | Approved | 39 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 32 |
| Pregabalin | Pfizer | Phase 3 | 40 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 47 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 26 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 38 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 39 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 37 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 40 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 17 |